TELA Bio (TELA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 9, 2026, to be held virtually at 10:00 a.m. EST.
Proxy materials and 2025 Annual Report are available online for review and voting.
Shareholders are encouraged to review all materials before voting and can request paper or electronic copies.
Voting matters and shareholder proposals
Election of three directors: Joseph Capper, Betty Jo Rocchio, and William Plovanic.
Ratification of KPMG LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation.
Approval of amendment to the 2019 Equity Incentive Plan to increase authorized shares by 3,500,000.
Approval to adjourn the meeting if insufficient votes are present for Proposal 4.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and all proposals listed.
Latest events from TELA Bio
- Q1 2026 revenue up 3% to $19.1M, with 41% international growth and net loss at $12.3M.TELA
Q1 202612 May 2026 - Board recommends approval of all proposals, including director elections and equity plan amendment.TELA
Proxy filing30 Apr 2026 - Achieved 16% revenue growth in 2025, set 8% growth guidance for 2026, and expanded sales force.TELA
Q4 202527 Apr 2026 - Strong product innovation and European growth position the company for profitability and market expansion.TELA
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase2 Feb 2026 - Q2 revenue up 11% to $16.1M; net loss widened; full-year growth guidance reaffirmed.TELA
Q2 20241 Feb 2026 - Q3 revenue rose 26% to $19M, with improved margins and strengthened liquidity.TELA
Q3 202415 Jan 2026 - Mesh market shift and operational gains set stage for robust growth and profitability.TELA
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - 2024 revenue rose 19%, with 2025 guidance targeting up to 27% growth despite sector risks.TELA
Q4 202425 Dec 2025 - Up to 2,000,000 shares registered for resale; proceeds from warrant exercise support corporate growth.TELA
Registration Filing16 Dec 2025